Fundraising Fox
Cellectar Biosciences
NASDAQ: CLRBMadison, US · Delaware corporation · 1 known investors
Find your way into Cellectar Biosciences
Sign up to see every warm intro you have to Cellectar Biosciences
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Cellectar Biosciences team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Cellectar Biosciences is a clinical-stage oncology company developing targeted cancer therapies using its proprietary PLE (phospholipid ether) delivery platform, which delivers therapeutic payloads directly to cancer cells. It focuses on advanced cancers with high unmet needs, including work related to triple-negative breast cancer.
Founders & leadership
JP
Jamey P. WeichertFounder, Director, CSO2002–2016Jamey P. Weichert is a researcher with expertise in targeted cancer imaging and therapy development, holding over 50 patents in the field. He co-founded Cellectar Biosciences and has served as faculty director of the University of Wisconsin Carbone Cancer Center's Small Animal Imaging and Radiotherapy facility.
JE
John E. Friend IIExecutive
JV
James V. CarusoExecutive
JL
Jarrod LongcorChief Operating OfficerJarrod Longcor is an executive at Cellectar Biosciences with over two decades of experience in the biopharmaceutical industry, including roles in business development, operations, and strategic planning for small to mid-sized biotech companies. He has led cross-functional teams in areas including product licensing, mergers and acquisitions, fundraising, and clinical and manufacturing operations.
CJ
Chad J. KoleanVP & CFOChad J. Kolean is an executive at Cellectar Biosciences with background in finance including roles as CFO and in treasury and controllership, with experience in financial planning, reporting, and information systems.
SL
Stefan LorenNamed on SEC filing
JP
John P. HamillNamed on SEC filing
Board
JN
John NeisBoard director
FW
Frederick W. DriscollBoard director
DJ
Douglas J. SwirskyBoard director
SA
Stephen A. HillBoard director
Investors · 1
Also in the syndicate · 1
Ladenburg Thalmann & Co. Inc.
Funding
SEC filings, press & company announcements$204.2M disclosed across 7 rounds · 2014–2026
- $140MraisedMay 2026 · 2 sourcesSource ↗
- $5.8MraisedOct 2025 · 2 sources
Ladenburg Thalmann & Co. Inc.
Source ↗
▶$24.5MraisedSep 2023 · 21 investors · BiotechnologyRule 506(b)
▶$24.5MraisedSep 2023 · 21 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Chad J. KoleanExecutive Officer
- Jarrod LongcorExecutive Officer
- Darrell Shane LeaExecutive Officer
- Frederick W. DriscollDirector
- James V. CarusoExecutive Officer, Director
- Stefan D. LorenDirector
- John NeisDirector
- Asher Alban Chanan-KahnDirector
- Douglas J. SwirskyDirector
- Andrei ShustovExecutive Officer
- Offering amount
- $24.5M
- Amount sold
- $24.5M
- Minimum investment
- $84.4K
- Sales commissions
- $1.4M
- Placement agents
- Oppenheimer & Co. Inc.
- First sale
- Sep 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$20.5MraisedJan 2021 · 16 investors · PharmaceuticalsRule 506(b)
▶$20.5MraisedJan 2021 · 16 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Dov ElefantExecutive Officer
- James V. CarusoExecutive Officer, Director
- Frederick W DriscollDirector
- Stephen A. HillDirector
- John FriendDirector
- John NeisDirector
- Douglas J. SwirskyDirector
- Jarrod LongcorExecutive Officer
- Stefan LorenDirector
- Offering amount
- $20.5M
- Amount sold
- $20.5M
- Sales commissions
- $1.4M
- Placement agents
- Oppenheimer & Co. Inc
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5MraisedMay 2019 · 11 investors · PharmaceuticalsRule 506(b)
▶$5MraisedMay 2019 · 11 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- James V. CarusoExecutive Officer, Director
- Stephen A. HillDirector
- Jarrod LongcorExecutive Officer
- Douglas J. SwirskyDirector
- Frederick W DriscollDirector
- Charles T. BernhardtExecutive Officer
- John NeisDirector
- Stefan LorenDirector
- Offering amount
- $14.6M
- Amount sold
- $5M
- Sales commissions
- $378.4K
- Placement agents
- Roth Capital Partners, LLC
- First sale
- May 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7.8MraisedOct 2017 · 3 investors · PharmaceuticalsRule 506(b)
▶$7.8MraisedOct 2017 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Frederick W. DriscollDirector
- John E. Friend IIExecutive Officer
- Douglas J. SwirskyDirector
- Stefan LorenDirector
- Stephen A. HillDirector
- James V. CarusoExecutive Officer, Director
- Jarrod LongcorExecutive Officer
- John P. HamillExecutive Officer
- John NeisDirector
- Offering amount
- $7.8M
- Amount sold
- $7.8M
- Sales commissions
- $582.5K
- Placement agents
- Landenburg Thalmann & Co. Inc.
- First sale
- Oct 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$617.5KraisedAug 2014 · 8 investors · PharmaceuticalsRule 506(b)
▶$617.5KraisedAug 2014 · 8 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Stephen A. HillDirector
- Jamey P. WeichertExecutive Officer, Director
- Paul BernsDirector
- Simon PedderExecutive Officer, Director
- Chad J. KoleanExecutive Officer
- John NeisDirector
- Offering amount
- $1M
- Amount sold
- $617.5K
- First sale
- Aug 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
NasdaqNasdaq operates a technology infrastructure platform for financial markets across three business segments: Capital Access Platforms (which includes listing services, indices, and analytics tools), Financial Technology (comprising compliance, regulatory, and capital markets software), and Market Services (equities and derivatives trading operations). The company serves financial institutions, listed companies, investment managers, and regulatory agencies globally.
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Seeking AlphaSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Companies working in the same space as Cellectar Biosciences.
Non-dilutive funding · 4 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2021 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2007 | $150.2K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Cellectar Biosciences do?
- Cellectar Biosciences is a clinical-stage oncology company developing targeted cancer therapies using its proprietary PLE (phospholipid ether) delivery platform, which delivers therapeutic payloads directly to cancer cells. It focuses on advanced cancers with high unmet needs, including work related to triple-negative breast cancer.
- Who founded Cellectar Biosciences?
- Cellectar Biosciences was founded by Jamey P. Weichert.
- How much funding has Cellectar Biosciences raised?
- Cellectar Biosciences has disclosed $204.2M raised across 7 rounds.
- Where is Cellectar Biosciences headquartered?
- Cellectar Biosciences is headquartered in Madison, US.